证券代码：002742 证券简称：*ST 三圣 公告编号：2025-66 号 重庆三圣实业股份有限公司 关于控股股东所持公司部分股份 将被二次司法拍卖的提示性公告 2、鉴于本次股东部分股份被司法拍卖事项尚处于公示阶段，根据相关规定 法院有权在拍卖开始前、拍卖过程中，中止拍卖或撤回拍卖，后续可能涉及竞 拍、缴款、股权变更过户等环节，拍卖结果存在不确定性。 一、控股股东股份被拍卖的基本情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次司法处置标的为公司控股股东潘先文先生持有的公司 280 万股股份， 占公司总股本的 0.6481%。本次司法拍卖事项不会导致公司控制权发生变更，不 会对公司的正常生产经营产生重大影响。 重庆三圣实业股份有限公司（以下简称"公司"）控股股东潘先文先生所持 280 万股公司股份于 2025 年 11 月 25 日 10 时起至 2025 年 11 月 26 日 10 时止在 淘宝网司法拍卖平台上进行第一次拍卖，显示结果为流拍，具体内容详见公司分 别于 2025 年 10 月 25 日、2025 年 11 月 27 ...

证券代码：002742 证券简称：三圣股份 公告编号：2025-65 号 重庆三圣实业股份有限公司 关于控股股东所持公司股份被司法拍卖流拍的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆三圣实业股份有限公司（以下简称"公司"）于 2025 年 10 月 25 日在巨 潮资讯网上披露了《关于控股股东所持公司股份将被司法拍卖的提示性公告》（公 告编号：2025-56），公司控股股东潘先文先生持有的公司 280 万股股份于 2025 年 11 月 25 日 10 时起至 2025 年 11 月 26 日 10 时止在淘宝网司法拍卖平台上（网 址：https://sf.taobao.com/）进行司法拍卖。根据淘宝网司法拍卖平台显示的 拍卖结果，本次拍卖流拍，具体情况如下： 重庆三圣实业股份有限公司董事会 1、本次控股股东所持有公司的股份司法拍卖流拍事项不会对公司的生产经 营产生重大影响。 2、公司将持续关注重庆市北碚区人民法院对上述公司股份后续处理的进展 情况，并按照相关规定及时履行信息披露义务。公司所有信息均以在指定媒体刊 登的信息为准。敬请广大投资者 ...

Core Points - Chongqing Sansheng Industrial Co., Ltd. has received a total of RMB 254,200,000.00 from all restructuring investors as of November 24, 2025 [1][2] - The restructuring investment agreements were signed with Hebei Jiheng Group Co., Ltd. and its designated financial investors, which include Shenzhen High-tech Investment Group Co., Ltd. and Chongqing Leiden Investment Fund Management Co., Ltd. [1] - The total restructuring investment amount was required to be paid within 30 days after the court's approval of the restructuring plan [1] Restructuring Investment Agreement - The restructuring investment agreements were signed on December 18 and December 23, 2024, with a total investment amount of RMB 254,200,000.00 [1] - The agreements stipulate that all restructuring investors must pay the total investment amount within the specified timeframe [1] Payment Status - As of November 24, 2025, the management account has received the full amount of the restructuring investment from all investors [2]

Group 1: Financial Products and Investment Performance - The issue of inflated returns on bank wealth management products has gained significant attention, with many investors reporting discrepancies between advertised and actual returns [1] - Industry experts call for standardized performance displays and emphasize the need for investors to develop a more professional and rational understanding of performance benchmarks [1] - Liang Hong, a prominent private equity manager, publicly apologized for underperforming against major indices, attributing the decline to three main factors: heavy investments in innovative drugs, hardware companies, and stablecoin stocks [1][2] Group 2: Robotics and Electric Vehicles - The Ministry of Industry and Information Technology announced the establishment of a standardization committee for humanoid robots, with representatives from several listed companies included [2] - According to TrendForce, global sales of new energy vehicles reached 5.39 million units in Q3 2025, marking a 31% year-on-year increase, with battery electric vehicles (BEVs) growing by 48% [2] Group 3: Corporate Developments and Investments - Tuozhu denied reports of Tencent's investment in its latest funding round, stating that no current financing is taking place [3] - Jiangxi Changyun announced plans to publicly transfer land use rights and assets for 7.787 million yuan [5] - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund focused on the intelligent industry [6] - Jusaylong intends to increase its subsidiary's capital by 170 million yuan through a debt-to-equity swap [7] - ST Sansheng received 254 million yuan from restructuring investors [8] - Lege Co., Ltd. plans to repurchase shares worth 40 to 80 million yuan [9] - Petty Co., Ltd. announced a share buyback plan of 50 to 70 million yuan [11] Group 4: Market Performance - The market showed a rebound with all major indices closing in the green, driven by strong performances in the aerospace, military, and AI application sectors [15] - The total trading volume in the Shanghai and Shenzhen markets was 1.73 trillion yuan, reflecting a decrease from the previous trading day [15]

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Core Points - *ST San Sheng has received a total of RMB 254,200,000.00 from all restructuring investors as of November 24, 2025, marking the completion of all restructuring investment payments [1] Financial Summary - The total amount received from restructuring investors is RMB 254.2 million [1] - All restructuring investors have fully paid their respective investment amounts [1]

重庆三圣实业股份有限公司 关于收到重整投资人全部重整投资款的公告 证券代码：002742 证券简称：*ST三圣 公告编号：2025-64号 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 如公司被宣告破产，根据《深圳证券交易所股票上市规则》（以下简称《深交 所股票上市规则》）第 9.4.18 条的相关规定，公司股票将面临被终止上市的风 险。 2、因公司 2024 年度审计后净资产为负值，根据《深交所股票上市规则》 9.3.1 的相关规定，公司股票交易被实施退市风险警示。若公司 2025 年度出现 重庆三圣实业股份有限公司（以下简称"三圣股份"或"公司"）于 2025 年 11 月 24 日收到管理人的通知，管理人账户已收到全体重整投资人支付的全 部重整投资款。现将相关情况公告如下： 一、重整投资协议签署情况 2024 年 12 月 18 日、12 月 23 日，三圣股份与重整投资人河北冀衡集团有 限公司（以下简称"河北冀衡集团"）及其指定的财务投资人深圳市高新投集 团有限公司（以下简称"深圳高新投"）、重庆镭登恩私募证券投资基金管理 有限公司（以下简称"重庆镭 ...

Core Points - *ST San Sheng reached the daily limit of 5.11 yuan, with a rise of 4.96%, and a total market value of 2.104 billion yuan on November 24, 2025 [1] - The company’s restructuring plan has been approved by the court, allowing it to avoid direct bankruptcy liquidation, with a high approval rate from creditors [2] - The introduction of strategic investor Jiheng Group will provide at least 200 million yuan in cash flow support over three years, enhancing the company's core competitiveness in the pharmaceutical sector [2] - The overall performance of the ST sector was active on the same day, contributing to *ST San Sheng's stock price increase, supported by net inflows from major funds [2] - Technical indicators show a bullish trend for the stock, with MACD forming a golden cross and the price breaking through short-term moving average resistance [2]

Group 1 - The core point of the article is that *ST San Sheng (002742.SZ) has received a civil ruling from the Chongqing Fifth Intermediate People's Court, which approves the company's restructuring plan and terminates the restructuring process [1] Group 2 - The court's decision is documented in the civil ruling number (2025) Yu 05 Po 297, indicating the formal legal proceedings related to the company's restructuring [1] - The approval of the restructuring plan marks a significant step for *ST San Sheng, potentially impacting its operational and financial stability moving forward [1]

Core Viewpoint - *ST San Sheng has received approval from the Chongqing Fifth Intermediate People's Court for its restructuring plan, marking the end of its restructuring process and the beginning of the execution phase of the plan [1] Group 1 - The Chongqing Fifth Intermediate People's Court has delivered a civil ruling approving the restructuring plan of Chongqing San Sheng Industrial Co., Ltd [1] - The company will now enter the execution phase of the approved restructuring plan [1]